MétaCan
Menu
← Back to cohort

S4858 Vedolizumab as a Second Line Biologic for Cronkhite-Canada Syndrome

2025· article· en· W7111386478 on OpenAlexaboutno aff

Bibliographic record

VenueThe American Journal of Gastroenterology · 2025
Typearticle
Languageen
FieldMedicine
TopicGenetic factors in colorectal cancer
Canadian institutionsnot available
Fundersnot available
KeywordsVedolizumabEsophagogastroduodenoscopyAzathioprineInfliximabPrednisoneColonoscopyCalprotectinAbdominal painInflammatory bowel disease

Abstract

fetched live from OpenAlex

Introduction: Cronkhite-Canada Syndrome (CCS) is a rare, debilitating disease characterized by diffuse gastrointestinal polyposis, protein-losing enteropathy, diarrhea, and dermatologic manifestations. Nutritional support and immune modulating therapies are the mainstay of treatment. We present a case of a patient with CCS treated with vedolizumab (VDZ) to highlight an alternative treatment not discussed in the current literature. Case Description/Methods: A 67-year-old woman was diagnosed with CCS in 2020 with classic clinical symptoms and findings on endoscopy and histology. At diagnosis, her blood inflammatory markers were normal but her calprotectin was elevated (486 mcg/g). She started infliximab (IFX) and azathioprine in 10/2020 with resolution of her clinical symptoms, normalization of her calprotectin, and substantially improved but had incomplete response on repeated endoscopic and histologic evaluations. Mild residual disease was noted in the antrum. Her azathioprine was stopped due to abdominal pain, distension, nausea and vomiting and due to abnormal liver tests including elevated bilirubin. IFX was continued and the dosing was optimized to 10 mg/kg every 8 weeks with drug levels of 13.9 ug/mL. In 8/2024, she had return of her clinical symptoms, though repeat calprotectin remained normal. A repeat esophagogastroduodenoscopy and colonoscopy subsequently showed severe edema and nodularity of the antrum/duodenum and mild nodularity in the right colon. She started oral prednisone and initiated VDZ 11/2024. She gained weight and had improvement of her nails, hair, abdominal pain, and diarrhea. After 4 infusions of VDZ and 4 weeks off corticosteroids, a repeat esophagogastroduodenoscopy/colonoscopy 3/2025 showed marked improvement with only a few areas of minimal disease activity, much improved compared to the endoscopic appearance with IFX. She has continued to feel well with last follow up on 4/8/25. Discussion: When untreated, CCS can be devastating with a 5-year mortality estimated at 55% due to complications from the disease. With immunosuppressant treatment and nutritional support, a recent case series found a 5-year overall survival at 93%. While corticosteroids can be effective for disease remission; steroid-sparing strategies are preferred. Thiopurines and IFX are well described in the literature for maintaining remission. This is the first case report to date of VDZ as an alternative therapy, particularly in a patient with secondary loss of response to IFX. This highlights an important alternative treatment option.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Case report · Consensus signal: Case report
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.009
GPT teacher head0.275
Teacher spread0.266 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designCase report
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueThe American Journal of Gastroenterology→Same topicGenetic factors in colorectal cancer→French-language works237,207→